Dose‐escalation of whole‐brain radiotherapy for brain metastasis in patients with a favorable survival prognosis
Open Access
- 13 December 2011
- Vol. 118 (15) , 3852-3859
Abstract
BACKGROUND: Patients with brain metastases who have a favorable survival prognosis may benefit from intensive treatments, including neurosurgery and radiosurgery. However, many patients cannot receive such treatments, and whole‐brain radiotherapy (WBRT) alone is their only option. The most common WBRT schedule is 30 grays (Gy) in 10 fractions. In this retrospective study, the authors investigated whether these patients benefit from a dose escalation beyond 30 Gy. METHODS: Data from 109 patients who received 30 Gy in 10 fractions were compared with 75 patients who received 40 Gy in 20 fractions. All patients had a favorable survival prognosis. Both groups were compared for local control (LC) and overall survival (OS). Subgroup analyses were performed for patients who had less radiosensitive tumors (N = 27) and for other patients (N = 157). RESULTS: The LC rate at 1 year was 28% after 30 Gy and 44% after 40 Gy (P = .064). On multivariate analysis, the 40 Gy dose was associated with improved LC (P = .047). The survival rate at 1 year was 50% after 30 Gy and 61% after 40 Gy (P = .007). On multivariate analysis, the 40 Gy dose was associated with improved OS (P = .008). On subgroup analysis of patients who had less radiosensitive tumors, the 1‐year LC rate was 7% after 30 Gy and 38% after 40 Gy (P = .031); and the 1‐year OS rate was 40% and 73%, respectively (P = .008). On subgroup analysis of patients who had other tumor types, the 1‐year LC rate was 31% after 30 Gy and 45% after 40 Gy (P = .26); and the 1‐year OS rate was 52% and 59%, respectively (P = .08). CONCLUSIONS: Escalation of the WBRT dose beyond 30 Gy resulted in better outcomes, particularly for patients who had less radiosensitive tumors. Cancer 2012. © 2011 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Scoring Systems to Estimate Intracerebral Control and Survival Rates of Patients Irradiated for Brain MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Surgical Resection Followed by Whole Brain Radiotherapy Versus Whole Brain Radiotherapy Alone for Single Brain MetastasisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Whole‐brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastasesCancer, 2007
- Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastasesCancer, 2007
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain MetastasesJournal of Clinical Oncology, 2003
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Chemotherapy of Brain Metastases from Lung Carcinoma: A Controlled Randomized StudyNeurosurgery, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958